H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-059457 Act: 34 Size: 324 KB 网页链接
$Cytosorbents(CTSO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001410578-24-000703 Act: 34 Size: 6 MB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 5.03 and 9.01 Accession Number: 0001104659-24-057514 Act: 34 Size: 357 KB 网页链接
$Cytosorbents(CTSO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-049520 Act: 34 Size: 416 KB 网页链接
$Cytosorbents(CTSO)$ ARS Annual Report to Security Holders Accession Number: 0001104659-24-049524 Act: 34 Size: 15 MB 网页链接
$Cytosorbents(CTSO)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-24-049498 Act: 34 Size: 1 MB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-043790 Size: 9 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-043792 Size: 5 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-043789 Size: 5 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-043788 Size: 9 KB 网页链接